arrow down

Stock information details

  • Share data
  • Ownership
  • Indices
  • Analysts
  • Consensus
  • Paper shares

Get an overview of Novozymes' share price development and analyze the performance.

Share data

Ownership

Novozymes’ stock consists of two types: A and B shares. Both shares have a nominal value of DKK 2 per share, but an A share carries 10 times as many votes as a B share.

At year-end 2019, Novozymes had more than 52,000 shareholders, of whom 95% were private shareholders in Denmark. Around fifty institutional investors, including Novo Holdings A/S, owned approximately 50% of the B shares. Roughly 70% of the B shares were held outside of Denmark. Novozymes held 4.1% of the B shares, equivalent to 3.3% of the total common stock. Novo Holdings A/S held 25.5% of the total common stock and, through its holding of the A stock and a proportion of the B stock (20,461,400 shares), controlled 72.0% of the votes. Novo Holdings A/S is wholly owned by the Novo Nordisk Foundation, and Novozymes is therefore included in the consolidated financial statements of the Novo Nordisk Foundation.

The Novo Nordisk Foundation wishes to be an “Engaged Owner” in relation to Novozymes and apply engaged ownership objectives and principles which among other things are described in ‘Objectives & Principles for engaged ownership in relation to Novo Nordisk A/S and Novozymes A/S’, cf. www.novonordiskfonden.com. The Novo Nordisk Foundation supports Novozymes in achieving its vision, ensuring competitive financial results and adhering to the Charter for Companies in the Novo Group. All strategic and operational matters are solely decided by the Board and the Executive Management of Novozymes.

Analysts

Names and analyst details of the financial institutions covering Novozymes with equity research.




Company Analyst Country
ABG Sundal Collier (analyst changeover) Denmark
Alm. Brand Markets Michael Friis Jørgensen Denmark
Midtermolen 7,
2100 Copenhagen
AlphaValue Virendra Singh Chauhan France
48 Boulevard des Batignolles,
Paris 75017

v.chauhan@alphavalue.eu
+91 (0) 120 4508000 (Ext: 1265)
Sector(s) covered: Medical Technology/Personal care/Gambling-Gaming

Bank of America Merrill Lynch Matthew Yates UK

2 King Edward St,
London EC1A 1HQ

matthew.yates@baml.com
+44 20 7996 4537
Sector(s) covered: Chemicals

Barclays Cezara Lozneanu UK

5 The North Colonnade, Canary Wharf,
London E14 4BB

Berenberg Sebastian Bray UK

60 Threadneedle Street,
London EC2R 8HP

sebastian.bray@berenberg.com
+44 20 3753 3011
Sectors: chemicals
Regions: Europe

Bernstein Günther Zechmann UK

50 Berkeley St,
London W1J 8HA

gunther.zechmann@bernstein.com
+44 20 7170 5019
Sectors: chemicals
Regions: Europe

Carnegie Lars Topholm Denmark

Overgaden Neden Vandet 9B,
1414 Copenhagen

Citigroup Tom Wrigglesworth UK

Citigroup,
33 Canada Square,
Canary Wharf,
London E14 5LB

thomas.wrigglesworth@citi.com
+44 207 986 4252
Sector(s) covered: Chemicals & Basic Materials

Credit Suisse Samuel Perry UK

One Cabot Square,
London E14 4QJ

samuel.perry@credit-suisse.com
+44 207 888 1583
Sectors: Specialty chemicals

Danske Bank Jonas Guldborg Hansen Denmark

Holmens Kanal 2-12,
1092 Copenhagen

jonah@danskebank.dk
+45 45 12 80 49
Sectors: Food and Beverage

Deutsche Bank Virginie Boucher-Ferte UK

105/108 Old Broad St,
London EC2N 1EN

virginie.boucher-ferte@db.com
+44 20 7545 7940
Sectors: chemicals
Regions: Europe

DNB Rune Majlund Dahl UK

20 St. Dunstan's Hill,
London EC3R 8HY

Exane BNP Paribas Heidi Vesterinen
Nicola Tang
UK

1 Hanover St,
London W1S 1YZ

Goldman Sachs Georgina Iwamoto UK

Plumtree Court,
25 Shoe Lane,
London EC4A 4AU

georgina.iwamoto@gs.com
+44 (0) 207 051 8362
Sector(s) covered: European Chemicals

Handelsbanken Annette Lykke Denmark

Havneholmen 29,
1561 Copenhagen

anly05@handelsbanken.dk
+45 4679 1295
Covered Novozymes A/S since: 2015
Sectors: medtech and foodtech

Jefferies International Laurence Alexander United States

520 Madison Avenue,
10th Floor, New York,
NY 10022

J.P. Morgan Jeff Zekauskas United States

383 Madison Avenue
New York, NY 10179

Kepler Cheuvreux (analyst changeover) Netherlands
Morningstar Rob Hales Netherlands

De Entrée 246
1101 EE Amsterdam

Nordea Michael Novod Denmark

Groenjordsvej 10,
2300 Copenhagen

Nykredit Bank Klaus Kehl Denmark

Kalvebod Brygge 47,
1780 Copenhagen

Redburn Ranulf Orr UK

10 Aldermanbury,
London EC2V 7RF

SEB Søren Samsøe Denmark

Bernstorffsgade 50,
1577 Copenhagen

soren.samsoe@enskilda.dk
+45 3328 3306
Sectors: food, beverages, ingredients and retail
Regions: Nordic

Sydbank (analyst changeover) Denmark
UBS Andrew Stott UK

5 Broadgate,
London EC2M 2QS

andrew.stott@ubs.com
+44 (0) 207 567 9227
Sectors: European chemicals

Consensus

Paper shares

Conversion of physical share certificates into registered shares

Holders of physical share certificates and interim certificates in former Nordisk Gentofte A/S and Novo Industri A/S are entitled to convert these into registered shares in Novozymes A/S and Novo Nordisk A/S.
Holders of such certificates are thus encouraged to contact Danske Bank, Corporate Actions, via contact details below no later than November 4, 2018 in order to have their shareholdings registered and the physical certificates converted into registered shares in Novozymes A/S and Novo Nordisk A/S.
If the conversion is not completed on November 4, 2018, the corresponding shares will be sold pursuant to the Danish Companies Act. Holders of physical share certificates and interim certificates will be entitled to collect the net proceeds of the share sale within a period of 3 years following the sale, November 4, 2021.
Click here to see the embedded announcement as published on Virk.dk for further information (in Danish).

The above applies to holders of physical share certificates and interim certificates in former Nordisk Gentofte A/S and Novo Industri A/S only and does not affect shareholders of registered shares in Novozymes A/S.

Danske Bank, 3886 Corporate Actions,
Holmens Kanal 2-12, 1092 København K,
Telephone: (+45) 45 14 36 94
E-mail: corporate.actions@danskebank.dk